Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroki Wada is active.

Publication


Featured researches published by Hiroki Wada.


Journal of Medicinal Chemistry | 2010

Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept

Ayumu Kurimoto; Kazuki Hashimoto; Tomoaki Nakamura; Kei Norimura; Haruhisa Ogita; Haruo Takaku; Roger Victor Bonnert; Tom McInally; Hiroki Wada; Yoshiaki Isobe

Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC(50) 50 nM) and rapidly metabolized by human plasma (T(1/2) 2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.


Toxicology and Applied Pharmacology | 2013

Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats

Peter Stewart Gilmour; Patrick J. O'Shea; Malbinder Fagura; James Pilling; Hitesh Sanganee; Hiroki Wada; Paul Courtney; Stefan Kavanagh; Peter A. Hall; K. Jane Escott

Wnt activation by inhibiting glycogen synthase kinase 3 (GSK-3) causes bone anabolism in rodents making GSK-3 a potential therapeutic target for osteoporotic and osteolytic metastatic bone disease. To understand the wnt pathway related to human disease translation, the ability of 3 potent inhibitors of GSK-3 (AZD2858, AR79, AZ13282107) to 1) drive osteoblast differentiation and mineralisation using human adipose-derived stem cells (hADSC) in vitro; and 2) stimulate rat bone formation in vivo was investigated. Bone anabolism/resorption was determined using clinically relevant serum biomarkers as indicators of bone turnover and bone formation assessed in femurs by histopathology and pQCT/μCT imaging. GSK-3 inhibitors caused β-catenin stabilisation in human and rat mesenchymal stem cells, stimulated hADSC commitment towards osteoblasts and osteogenic mineralisation in vitro. AZD2858 produced time-dependent changes in serum bone turnover biomarkers and increased bone mass over 28 days exposure in rats. After 7 days, AZD2858, AR79 or AZ13282107 exposure increased the bone formation biomarker P1NP, and reduced the resorption biomarker TRAcP-5b, indicating increased bone anabolism and reduced resorption in rats. This biomarker profile was differentiated from anabolic agent PTH1-34 or the anti-resorptive Alendronate-induced changes. Increased bone formation in cortical and cancellous bone as assessed by femur histopathology supported biomarker changes. 14 day AR79 treatment increased bone mineral density and trabecular thickness, and decreased trabecular number and connectivity assessed by pQCT/μCT. GSK-3 inhibition caused hADSC osteoblastogenesis and mineralisation in vitro. Increased femur bone mass associated with changes in bone turnover biomarkers confirmed in vivo bone formation and indicated uncoupling of bone formation and resorption.


Journal of Medicinal Chemistry | 2018

Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists

Cristina Gardelli; Hiroki Wada; Asim Ray; Moya Caffrey; Antonio Llinas; Igor Shamovsky; Joakim Tholander; Joakim Larsson; Ulf Sivars; Leif Hultin; Ulf Andersson; Hitesh Sanganee; Kristina Stenvall; Brith Leidvik; Karin Gedda; Lisa Jinton; Marie Rydén Landergren; Kostas Karabelas

Cachexia and muscle wasting are very common among patients suffering from cancer, chronic obstructive pulmonary disease, and other chronic diseases. Ghrelin stimulates growth hormone secretion via the ghrelin receptor, which subsequently leads to increase of IGF-1 plasma levels. The activation of the GH/IGF-1 axis leads to an increase of muscle mass and functional capacity. Ghrelin further acts on inflammation, appetite, and adipogenesis and for this reason was considered an important target to address catabolic conditions. We report the synthesis and properties of an indane based series of ghrelin receptor full agonists; they have been shown to generate a sustained increase of IGF-1 levels in dog and have been thoroughly investigated with respect to their functional activity.


Archive | 2005

9-Substituted 8-oxoadenine compound

Ayumu Kurimoto; Kazuki Hashimoto; Yoshiaki Isobe; Stephen Brough; Ian Millichip; Hiroki Wada; Roger Victor Bonnert; Thomas Mcinally


Tetrahedron Letters | 2012

Facile and regioselective synthesis of novel 2,4-disubstituted-5-fluoropyrimidines as potential kinase inhibitors

Hiroki Wada; Lili Cheng; Ji Jiang; Zhigan Jiang; Jun Xie; Tao Hu; Hitesh Sanganee; Tim Luker


Archive | 2017

imidazoquinolinas com propriedades imunomoduladoras

Hiroki Wada; Roger Victor Bonnert; Stephen Thom; Thomas Mcinally


Archive | 2008

Imidazoquinolines dotées de propriétés immuno-modulatrices

Roger Victor Bonnert; Thomas Mcinally; Stephen Thom; Hiroki Wada


Archive | 2008

Imidazochinoline mit immunmodulierenden eigenschaften

Roger Victor Bonnert; Thomas Mcinally; Stephen Thom; Hiroki Wada


Archive | 2007

Dérivés de la 8-oxoadénine agissant comme modulateurs de tlr7

Anthony Ronald Cook; Tom McInally; Stephen Thom; Hiroki Wada


Archive | 2006

Purinderivate mit immunmodulierenden eigenschaften

Thomas Mcinally; Stephen Thom; Hiroki Wada

Collaboration


Dive into the Hiroki Wada's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephen Thom

Loughborough University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuki Hashimoto

Dainippon Sumitomo Pharma Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom McInally

Loughborough University

View shared research outputs
Researchain Logo
Decentralizing Knowledge